NYU Langone and NYU Grossman in the News
Pope Leo XIV's road to recovery
Telemundo 47
The latest medical report from Gemelli Hospital in Rome brings hopeful news. According to specialists, the clinical picture points to a good recovery. Jorge M. Mercado, MD, associate section chief of pulmonary and critical care at NYU Langone Hospital—Brooklyn, said that as it seems to be an early-stage lung cancer, the surgery he has undergone is a sufficient treatment.
10/14/2026
Medical Daily
A new analysis of 6,617 US pregnancies led by NYU Langone Health researchers linked a plastic softener, DINCH, to slightly smaller newborns. The study found that each tenfold increase in the chemical's level in a pregnant person's urine was associated with a 27-gram drop in birth weight. Lead author Leonardo Trasande, MD, MPP, the Jim G. Hendrick, MD, Professor of Pediatrics, professor of population health, and director of the Division of Environmental Pediatrics and the Center for the Investigation of Environmental Hazards at NYU Langone, noted that these findings suggest a chemical promoted as a safer replacement for phthalates may affect fetal growth. The observational study demonstrates an association, not direct causation.
Also reporting was: The New Lede
10/13/2026
The difficulty of diagnosing anorexia in the GLP-1 era *
The New York Times
Doctors are increasingly concerned that GLP-1 weight-loss drugs are masking or causing anorexia, as drug side effects can mirror eating disorder symptoms. An international coalition has released new guidelines advising physicians to screen patients for eating disorders before prescribing these medications. According to Melanie R. Jay, MD, director of NYU Langone's Comprehensive Program on Obesity, implementing these measures is difficult because obesity doctors and eating disorder specialists rarely interact, and many physicians lack training in identifying signs of anorexia.
10/16/2026
NYU Langone Health opens new imaging center in NYC
Imaging Technology News
NYU Langone Health has opened a new 28,000-square-foot imaging facility, NYU Langone Radiology—Upper West Side, in New York City. The center offers advanced technologies to support breast, neurological, cardiovascular, and cancer care. According to Oren Cahlon, MD, executive vice president, vice dean for clinical affairs and strategy, and chief clinical officer at NYU Langone Health, the location advances the mission to deliver premier imaging care locally. Michael P. Recht, MD, chair of the Department of Radiology at NYU Grossman School of Medicine, noted that earlier, more accurate diagnoses help guide personalized treatment and improve patient outcomes.
10/14/2026
Unexpected retatrutide side effects reported by Reddit users
Medscape
An analysis of Reddit user comments on the investigational drug retatrutide found unexpected reported side effects, including increased appetite and fatigue, which differed from those in clinical trials. Commenting on the findings, Priya Jaisinghani, MD, obesity specialist at NYU Langone Health, noted that non-FDA-approved versions sold on the gray market may contain different substances, leading to varying adverse effects. She stressed the importance of educating patients about these risks, encourages nonjudgmental clinical discussions, and supports reporting adverse events to the FDA to improve safety surveillance.
10/14/2026
9 things that can make Sjögren’s symptoms worse
HealthCentral
An article details nine triggers that can worsen symptoms of Sjögren's syndrome, including overexertion, poor sleep, dehydration, stress, and certain medications. Processed foods, allergies, and a lack of exercise can also contribute to flares. Experts at NYU Langone Health advise that the acid in coffee and chemical compounds in alcohol can aggravate or damage sensitive mouth tissues. They recommend less acidic beverages like green or herbal teas, which may have anti-inflammatory properties, and sticking to unsweetened, non-carbonated drinks.
10/14/2026
Elevance Health Foundation launched a prize program for patient safety initiatives. Here's why
Fierce Healthcare
The Elevance Health Foundation has launched a new prize program to support patient safety, awarding a total of $4 million to four organizations. NYU Grossman School of Medicine was selected as one of the winners for its program targeting medication errors. The initiative seeks to identify and scale community-based solutions for critical patient safety risks, including fall prevention and health literacy. Other inaugural winners are Care Synergy, the Public Health Institute's Population Health Innovation Lab, and the Parkland Center for Clinical Evaluation. The foundation aims to foster greater community involvement in patient safety dialogue through this program.
Also reporting was: Inside Philanthropy
10/15/2026
AAO 2026: The optic nerve is the barrier to sight in eye transplant
Ophthalmology Times
Speaking at the American Academy of Ophthalmology 2026 Annual Meeting, Vaidehi S. Dedania, MD, associate professor in the Department of Ophthalmology at NYU Grossman School of Medicine, discussed the future of whole human eye transplants, noting the optic nerve remains the primary barrier to restoring sight. The first successful transplant at NYU Langone Health also included a partial face, which was crucial for maintaining blood and nerve supply. Current research focuses on reducing ischemia time and preserving the donor eye. While restoring full vision is a long-term goal, the procedure could soon help trauma patients regain light perception.
10/15/2026
Antibiotics damage the gut microbiome—and sugar might make it worse
Technology Networks
A study in Nature finds that a sugary diet combined with antibiotic treatment may worsen gut microbiome damage. Research involving blood cancer patients showed that sugar intake during antibiotic exposure led to reduced microbial diversity and an increase in harmful bacteria. According to Jonas Schluter, PhD, assistant professor in the Department of Microbiology at at NYU Grossman School of Medicine, who was involved in the study, these causal effects can be amplified in vulnerable patient populations. The findings suggest that temporarily reducing sugar intake while taking antibiotics is a low-risk way to mitigate microbiome injury.
10/15/2026
First new sunscreen type in 25 years hits U.S. store shelves
MedPage Today
The FDA has approved bemotrizinol, or BEMT, the first new sunscreen chemical introduced in the US in over twenty-five years. Now available on store shelves, the ingredient offers broad-spectrum protection against UVA and UVB rays without the white streaking common with mineral sunscreens. Jennifer A. Stein, MD, PhD, the Stewart J. Rahr Professor of Dermatology in the Ronald O. Perelman Department of Dermatology at NYU Langone Health, commented that BEMT has decades of safety data and its large molecules limit skin absorption, addressing a concern associated with older chemical-based ingredients. She added it is a good option for people who dislike the feel of mineral sunscreens.
Also reporting was: Morning Ag Clips, PBS, The Miami Times, Los Angeles Times, The Sentinel Colorado, Head Topics, Dnyuz, Head Topics
10/14/2026
DOT to open 13,000 Manhattan parking spaces to taxi, ride-share drivers
Labor New York
New York City's Department of Transportation will soon make 13,000 commercially metered parking spaces in Manhattan's congestion zone available to taxi and for-hire drivers. The pilot program addresses years of complaints from drivers about a lack of access to rest areas and bathrooms. The article notes that according to a study by the Department of Urology at NYU Langone Health, career drivers can suffer from health issues like bladder damage, infertility, or prostate cancer due to habitually suppressing the urge to use the bathroom. The plan has received mixed reactions from community boards and trucking groups.
10/14/2026
After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
STAT
Gary Keblish, a patient diagnosed with high-risk melanoma in 2019, shared his experience participating in a clinical trial for an mRNA cancer vaccine developed by Merck and Moderna combined with Keytruda. In remarks at the STAT Summit, Keblish described his treatment under the care of the late Jeffrey Weber, MD, PhD, former deputy director of NYU Langone’s Perlmutter Cancer Center and co-leader of its Clinical Melanoma Program. He voiced gratitude for the medical team that supported him through his journey, noting that six years after his tumor was removed, he is back in the classroom teaching.
10/15/2026
Obesity linked to lower risk for mortality in dementia
HealthDay
A study led by Virginia W. Chang, MD, PhD, associate professor in the Department of Population Health at NYU Grossman School of Medicine, found that individuals with overweight or obesity at the time of a dementia diagnosis have lower mortality rates compared to those of normal weight. Published in the Journal of Alzheimer's Disease, the research showed Class I obesity was associated with a significantly lower risk of mortality. The findings suggest that weight status may be a useful prognostic indicator for survival and highlights nutrition's role in patient health.
10/14/2026
What the women in long-haul perimenopause wish they knew
Women's Health
An article explores the phenomenon of 'long-haul' perimenopause, noting that many women experience symptoms for a decade or more, often beginning as early as their thirties. Mariya Rozenfeld, DO, an obstetrician–gynecologist and an assistant professor in the Department of Obstetrics and Gynecology at NYU Langone Health, explains that menopause is confirmed after one year without a period. The piece discusses the wide range of debilitating symptoms, including mood changes, fatigue, and brain fog, which are often dismissed. It also covers treatment options like hormone replacement therapy and highlights the importance of finding a knowledgeable doctor and building a supportive community.
Also reporting was: Yahoo Health, Aol, MSN
10/14/2026
Meet the Minnies 2026 semifinalist candidates
Aunt Minnie
AuntMinnie.com has announced its semifinalist candidates for the 2026 Minnies awards, which recognize excellence in medical imaging. Among the nominees for Most Effective Radiology Educator is Andrew B. Rosenkrantz, MD, abdominal radiologist at NYU Langone. The campaign features over 100 semifinalists across 14 categories. Winners are selected by an expert panel through two voting rounds, with finalists announced in late October and winners in early November.
10/15/2026
Starting dialysis? Here’s what to expect
Black Doctor
In an article explaining dialysis, Nobuyuki Miyawaki, MD, chief of nephrology at NYU Langone Hospital—Long Island, an assistant dean of preclinical education, and an associate professor of medicine at NYU Grossman Long Island School of Medicine, outlines what patients can expect from the treatment. The piece details various dialysis methods and their impact on daily life, citing NYU Langone Health regarding potential side effects like cramping. It also discusses kidney transplantation as the preferred long-term solution for kidney failure, noting that NYU Langone has the highest transplant rate and shortest time to transplant in New York State.
10/13/2026
Orthopedics in the GLP-1 era: More surgical candidates, new risks
Becker's Spine Review
Orthopedic surgeons report that GLP-1 medications are expanding the pool of surgical candidates by helping patients lose weight, but also introduce new risks. While many patients now meet BMI thresholds for joint replacement, experts express concern over rapid weight loss leading to muscle and bone density loss, which can complicate rehabilitation. Surgeons emphasize the need for structured nutrition and strength training. Joseph D. Zuckerman, MD, chair of the Department of Orthopedic Surgery at NYU Langone Health, stated that there has been no noticeable impact as of yet, other than the need to change perioperative management.
10/15/2026
Optimizing first-line treatment selection across in early- and advanced-stage Hodgkin lymphoma
Oncology Learning Network
Catherine S. Diefenbach, MD, director of hematology translational research as well as director of the Clinical Lymphoma Program At NYU Langone’s Perlmutter Cancer Center, examines the evolving first-line treatment landscape for classical Hodgkin lymphoma. She compares nivolumab-based immunotherapy, brentuximab vedotin regimens, and established ABVD chemotherapy. Citing the S1826 and HD21 trials, she supports newer regimens for advanced-stage patients. For early-stage disease, however, she concludes that validated ABVD-based therapies should remain standard due to favorable long-term outcomes. Dr. Diefenbach also advises balancing progression-free survival with treatment toxicity and the financial burden of newer agents until more randomized clinical trial data is available.
10/14/2026
US medical residencies are flying blind on AI training, national survey finds
Scienmag
A national survey published in the Journal of General Internal Medicine finds that US internal medicine residency programs have not kept pace with the rapid integration of artificial intelligence into medicine. The research team, which included Verity E. Schaye, MD, MHPE, associate professor in the Department of Medicine at NYU Grossman School of Medicine, discovered that formal AI education is inconsistent and underdeveloped. The study highlights that while residents use AI tools widely, the lack of formal instruction on their reliability, risks, and proper application is a significant gap. Key barriers to implementing curricula include a shortage of faculty expertise and the rapid evolution of AI technology.
10/14/2026
Medical Daily
Thomas Sorenson, MD, plastic surgery resident, and Nikhil A. Agrawal, MD, clinical assistant professor in the Hansjorg Wyss Department of Plastic Surgery at NYU Grossman School of Medicine, described the case of a 59-year-old woman who had not seen a doctor in two decades. She presented with a malignant phyllodes tumor, a rare breast cancer, which led to the discovery of a separate, early colon cancer during her evaluation. Following operations for both cancers, the patient was healthy and disease-free at her one-year follow-up, highlighting the importance of thorough assessments.
10/14/2026
Continuously evolving cells help pancreatic cancer evade treatment and spread
Lifeboat Foundation
A study led by researchers at NYU Langone Health and its Perlmutter Cancer Center reveals how pancreatic cancer cells continuously reshape their genetic makeup to evade treatment. An analysis of nearly half a million cells from patient tumors provided new insights into how subpopulations of pancreatic cancer cells reconfigure their DNA over time. The research focused on pancreatic ductal adenocarcinoma, a form of cancer that is often difficult to treat and has a five-year survival rate of approximately 15%.
10/15/2026
New assay aids diagnosis of invasive aspergillosis
Medscape
A new urine assay, MycoMEIA, has been cleared by the FDA for diagnosing invasive aspergillosis (IA). Research found the test correctly identified 92% of IA cases and 88% of controls by detecting Aspergillus glycans in urine. Ryan Maves, MD, chief of medicine at NYU Langone Hospital—Brooklyn, who was not involved in the study, commented that a noninvasive test with high sensitivity would be a significant advance for clinicians and patients. He noted its potential for high-risk groups, such as those with post-viral IA, but emphasized that larger prospective studies are needed to determine its predictive values in practice.
10/14/2026
Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC
Clinical Trials Arena
Verastem Oncology's KRAS inhibitor, VS-7375, has shown promising clinical activity in a Phase I/II trial for patients with various advanced solid tumors. Manuel Hidalgo Medina, MD, co-director of the Gastrointestinal Cancer Center at NYU Langone Health, who is an investigator in the trial, noted the drug's significant molecular responses in patients with pancreatic cancer. Following the positive data, Verastem plans to advance the drug to a Phase III trial and will meet with the US Food and Drug Administration to review pivotal trial designs for first-line treatments in several cancers.
Also reporting was: Yahoo Finance, MSN
10/15/2026
What’s really inside breast milk? Scientists discover 7 molecules linked to how babies grow
SciTechDaily
A study led by researchers at NYU Grossman School of Medicine identified seven molecules in human milk linked to maternal nutrition and infant growth. Senior author Liat Shenhav, PhD, assistant professor in the Department of Microbiology and the Department of Obstetrics and Gynecology at NYU Grossman School of Medicine, explained the research offers insights into mammary gland biology. The team found a molecular pattern associated with supplementation and infant growth, suggesting some milk components respond to maternal nutrition. First author April Jauhal, PhD, of the Shenhav Lab at NYU Grossman School of Medicine, noted the findings highlight an integrative approach to maternal and infant health.
10/14/2026
Despite having the playbook, L.A. still failed to command the 2025 fires
Los Angeles Times
In an opinion piece, Kelly McKinney, vice president of Emergency Management and Enterprise Resilience at NYU Langone Health, argues that the 2025 Los Angeles fires exposed systemic failures in preparation and command, not a lack of frontline effort. McKinney contends the core issue is a widespread failure to implement lessons from past events, stemming from complacency. The column calls for California to improve catastrophe management by making state reimbursement for local response costs conditional on verified command qualifications, proactive activation, and large-scale joint exercises, ensuring accountability for implementing recommendations.
Also reporting was: Yahoo
10/15/2026
Nurse-led ED screening improves delirium detection in older adults
The Clinical Advisor
Research presented by Samantha Banker, MSN, AGACNP-BC, a board-certified geriatric nurse practitioner at NYU Langone Health, indicates that nurse-led assessment in the emergency department improves delirium detection in older adults. A study of 214 patients aged 65 and older found that 11% had a positive delirium screening. The findings support establishing systematic delirium prevention and management protocols in EDs, including geriatric-focused interventions and assessments led by advanced practice registered nurses. Ms. Banker concluded that routine screening can effectively identify at-risk patients, as delirium is prevalent and underdiagnosed.
10/14/2026
